Sage Rhino Capital’s GSK GSK Stock Holding History

Sage Rhino Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$356K	Sell	6,792 -357	-5%	-$18.9K	0.06%	190
2026 Q1	$395K	Buy	7,149 +246	+4%	+$13.3K	0.07%	165
2025 Q4	$339K	Sell	6,903 -2	-0%	-$93	0.06%	181
2025 Q3	$298K	Buy	6,905 +293	+4%	+$11.4K	0.06%	195
2025 Q2	$254K	Buy	6,612 +225	+4%	+$8.6K	0.05%	200
2025 Q1	$247K	Buy	6,387 +156	+3%	+$5.71K	0.06%	196
2024 Q4	$211K	Buy	6,231 +46	+0.7%	+$1.66K	0.05%	234
2024 Q3	$253K	Buy	6,185 +109	+2%	+$4.46K	0.06%	199
2024 Q2	$234K	Sell	6,076 -444	-7%	-$18.7K	0.06%	197
2024 Q1	$280K	Buy	6,520 +178	+3%	+$7.34K	0.07%	173
2023 Q4	$235K	Sell	6,342 -238	-4%	-$8.54K	0.06%	184
2023 Q3	$239K	Buy	+6,580	New	+$234K	0.07%	180
2022 Q3	–	Sell	-6,335	Closed	-$345K	–	197
2022 Q2	$345K	Buy	6,335 +151	+2%	+$8.34K	0.13%	130
2022 Q1	$337K	Buy	6,184 +326	+6%	+$17.7K	0.1%	154
2021 Q4	$323K	Buy	5,858 +788	+16%	+$41K	0.09%	156
2021 Q3	$242K	Buy	5,070 +364	+8%	+$18.3K	0.07%	169
2021 Q2	$234K	Buy	+4,706	New	+$226K	0.07%	172
2020 Q4	–	Sell	-4,554	Closed	-$214K	–	182
2020 Q3	$214K	Buy	4,554 +452	+11%	+$22.6K	0.1%	142
2020 Q2	$209K	Buy	+4,102	New	+$210K	0.11%	144
2020 Q1	–	Sell	-4,104	Closed	-$240K	–	152
2019 Q4	$240K	Buy	4,104 +269	+7%	+$15K	0.14%	126
2019 Q3	$205K	Buy	+3,835	New	+$197K	0.13%	131

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Sage Rhino Capital's GSK Position: Q2 2026 in Review

Sage Rhino Capital reduced its GSK (GSK) stake by 5% in Q2 2026, selling an estimated $18.9K and leaving 6,792 shares worth $356K. The position accounts for 0.06% of the portfolio, ranked #190.

Sage Rhino Capital first reported a position in GSK in Q3 2019 and has held it in 21 quarters since. The position peaked at $395K in Q1 2026. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Sage Rhino Capital held 6,792 shares of GSK worth $356K as of Q2 2026.
Sage Rhino Capital sold 357 GSK shares in Q2 2026, an estimated $18.9K.
GSK made up 0.06% of Sage Rhino Capital's portfolio in Q2 2026, its #190 holding.
Sage Rhino Capital first reported a position in GSK in Q3 2019 and has held it in 21 quarters since.
Sage Rhino Capital's GSK position peaked at $395K in Q1 2026.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Sage Rhino Capital's 13F filing for Q2 2026, filed 3 Aug 2026.